- Poster presentation
- Open Access
A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes
© Slingluff et al.; licensee BioMed Central Ltd. 2014
Published: 6 November 2014
The recMAGE-A3 protein has been administered intramuscularly (IM) with immunostimulant AS15 as an experimental immunotherapeutic. AS15 contains 3-O-desacyl-4'-monophosphoryl lipid A (MPL), QS-21, CpG 7909 and liposome. This MAGE-A3/AS15 immunotherapeutic has not been studied for intradermal (ID) or subcutaneous (SC) use. A clinical trial (NCT01425749) was initiated to test the hypotheses that ID/SQ administration is safe and may induce CD4+ and CD8+ T cell responses to MAGE-A3.
Patients and methods
Twenty-five eligible patients with resected stage IIB-IV MAGE-A3+ melanoma were randomized to 2 arms, treated with MAGE-A3/AS15 Immunotherapeutic IM (Arm A, n = 13) or ID/SC (Arm B, n = 12). Adverse events (CTCAE 4) were recorded. Antibody (Ab) responses to MAGE-A3 protein were assessed by ELISA assay. T cell responses were assessed by flow cytometry after intracellular cytokine staining (ICS) for multifunctional CD4+ and CD8+ responses to overlapping MAGE-A3 peptides, assaying lymphocytes from peripheral blood (PBMC) and sentinel immunized node (SIN), after one in vitro stimulation.
Multifunctional (IFNg and TNFα) T cell responses to MAGE-A3
% of CD4+ T cells
% of CD8+ T cells
Safety profiles were comparable for ID/SC and IM administration of the MAGE-A3/AS15 immunotherapeutic, which induced high-titer Ab, multifunctional CD4+ Th1 responses, and CD8+ responses when administered by either route. Immune responses were more readily detected in the SIN than in PBMC. These pilot data support further investigation of ID/SC immunization with antigen plus AS15 to support Th1 CD4+ responses and CD8+ responses. Production of Th1 cytokines IFNg and TNFα suggests the induced CD4+ responses may support CD8+ T cells. Other forms of antigen (e.g.: long peptides) may further support induction of CD8+ T cell responses in combination with AS15.
Funding source: GlaxoSmithKline Biologicals SA
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.